Author

admin

Browsing

A select group of lawmakers received their first closed-door briefing on Capitol Hill on Monday following the Trump administration’s weekend military strikes in Venezuela and the capture of President Nicolás Maduro — a meeting that quickly divided along political lines.

The roughly two-hour meeting deep in the bowels of Congress featured top administration officials providing a classified briefing to congressional leaders and the chairs and ranking members of the armed services, intelligence and foreign relations committees. 

None of the Trump officials, who included Secretary of State Marco Rubio, Attorney General Pam Bondi, CIA Director John Ratcliffe, Joint Chiefs of Staff Chair Gen. Dan ‘Raizin’ Caine and Secretary of War Pete Hegseth, spoke after the meeting. 

But a handful of lawmakers did, and questions still lingered about what exactly would come next for U.S. involvement in the country, if other similar operations would be carried out across the globe, and who exactly was running Venezuela.

House Speaker Mike Johnson, R-La., said that there was no expectation that the U.S. would be on the ground, nor would there be any ‘direct involvement in any other way beyond just coercing the interim government to to get that going.’

‘We are not at war,’ Johnson said. ‘We do not have U.S. armed forces in Venezuela, and we are not occupying that country.’

‘This is not a regime change,’ he continued. ‘This is a demand for change of behavior by a regime. The interim government is stood up now, and we are hopeful that they will be able to correct their action.’

House Foreign Affairs Committee Chair Brian Mast, R-Fl., echoed Johnson, and reiterated that the operation was a ‘specific law enforcement function that took place that took a significant obstacle out of the way for the Venezuelan people to go chart a new future.’ 

He didn’t expect further military action from the Trump administration in the country, either. 

‘These things are done before breakfast,’ Mast said. ‘They don’t do protracted war operations.’

However, Senate Minority Leader Chuck Schumer, D-N.Y., countered that the lengthy meeting ‘posed far more questions than it ever answered.’ 

One growing point of contention among lawmakers is just how directly involved the U.S. will be, given that Trump said that the U.S. would govern the country until a proper transition of power happened. 

Schumer said that the plan presented behind closed doors or the U.S. running Venezuela ‘is vague, based on wishful thinking and unsatisfying.’

‘I did not receive any assurances that we would not try to do the same thing in other countries,’ he said. ‘And in conclusion, when the United States engages in this kind of regime change and so called nation building, it always ends up hurting the United States. I left the briefing feeling that it would again.’

Schumer, along with Sens. Tim Kaine, D-Va., Adam Schiff, D-Calif., and Rand Paul, R-Ky., plan to force a vote later in the week on a war powers resolution that, if passed, would require the administration to get congressional approval before taking further military action in Venezuela. 

Senate Majority Leader John Thune, R-S.D., said that he was satisfied with the briefing and that ‘it was a very comprehensive discussion.’

Lawmakers will get another bite at the apple later in the week when Trump officials again return to Congress to provide a full briefing to lawmakers on Operation Absolute Resolve. 

Sen. Mark Warner, D-Va., and the top-ranking Democrat on the Senate Select Committee on Intelligence, lauded the military for a ‘brilliant execution’ of the mission, and noted that the region was better off without Maduro.

But, like Schumer, he was still searching for the next step. 

‘The question becomes, as policymakers, what happens the day after,’ Warner said. 

This post appeared first on FOX NEWS

David Morgan, publisher of the Morgan Report, weighs in on silver’s record-setting price rise and what could be next for the white metal heading into 2026.

‘We’re still in price discovery. I truly believe that,’ he said.

‘What the true price of silver is in US dollars, Canadian dollars, I do not know. I think it’s north of $100 in US dollar terms, but it could be much higher than that.’

Securities Disclosure: I, Charlotte McLeod, hold no direct investment interest in any company mentioned in this article.

This post appeared first on investingnews.com

Today’s pharmaceutical stocks are facing the challenges of government-imposed drug price caps, waning demand for COVID-19 vaccines and global stock market upheaval.

However, the industry’s major underlying drivers — higher rates of cancer and chronic disease — are still at play and not expected to dissipate.

The US reigns supreme in the pharma market, both in terms of drug demand and development. In 2025, 46 novel medicines were approved by the US Food and Drug Administration (FDA), compared to 50 such approvals in 2024.

Big pharma largely steals the show when people discuss pharmaceutical companies, but some small- and mid-cap NASDAQ pharma stocks have also made gains.

Read on to learn more about their activities this year.

1. Galectin Therapeutics (NASDAQ:GALT)

Year-to-date gain: 211.45 percent
Market cap: US$263.08 million
Share price: US$4.08

Galectin Therapeutics is developing therapies for patients with chronic liver disease and cancer.

The clinical-stage biopharma company’s lead drug candidate, carbohydrate-based belapectin, targets multiple inflammatory, fibrotic and malignant diseases by inhibiting the galectin-3 protein. Belapectin has been granted fast-track designation by the FDA.

In 2025, Galectin Therapeutics reported positive topline data from its Phase 2b/3 trial evaluating the efficacy and safety of using belapectin intravenously in patients with metabolic dysfunction-associated steatohepatitis (MASH) cirrhosis and portal hyper tension. The results demonstrated that belapectin significantly reduced the development of new esophageal varices and stabilized liver stiffness, demonstrating potential to halt the progression of MASH cirrhosis.

Galectin is currently designing its pivotal Phase 3 study intended to support a formal new drug application. Based on a December 2025 response from the FDA, the company said it believes it has achieved alignment with the agency on the patient population for its upcoming registration-level trials.

2. CytomX Therapeutics (NASDAQ:CTMX)

Year-to-date gain: 136.63 percent
Market cap: US$375.74 million
Share price: US$2.38

CytomX Therapeutics is a clinical-stage biopharma firm with a focus on developing safer, more effective oncology treatments. It collaborates with a number of leading oncology firms, including Amgen (NASDAQ:AMGN), Bristol-Myers Squibb (NYSE:BMY), Regeneron Pharmaceuticals (NASDAQ:REGN) and Moderna (NASDAQ:MRNA).

The company’s pipeline is based on its PROBODY therapeutic platform, which it uses to produce localized biologics that target tumors. This includes multiple treatment modalities such as antibody-drug conjugates, T-cell engagers and immune modulators such as cytokines. Its clinical-stage pipeline includes CX-2051 and CX-801.

In mid-May 2025, CytomX’s share price shot up significantly after the company provided its Q1 business update and closed on a US$100 million underwritten offering of common stock.

In the update, CytomX included positive interim clinical results for an ongoing Phase 1 dose escalation study of its lead candidate, CX-2051, in advanced colorectal cancer. The company has initiated further Phase 1 dose expansions, with data expected out by Q1 2026. In its Q3 update, CytomX reported it plans to initiate a Phase 1b study of CX-2051 in combination with bevacizumab to treat colorectal cancer, also expected in the first quarter of the new year.

On May 19, the first patient was dosed in CytomX’s ongoing Phase 1 dose escalation study with CX-801 in combination with Merck & Company’s (NYSE:MRK) Keytruda in patients with metastatic melanoma. The company released initial translational data in November.

3. Eton Pharmaceuticals (NASDAQ:ETON)

Year-to-date gain: 25.37 percent
Market cap: US$450.53 million
Share price: US$16.80

Eton Pharmaceuticals is a high-growth pharmaceutical company developing treatments for rare diseases. Headquartered in Deer Park, Illinois, the company has successfully transitioned from a development-stage firm into a commercially focused entity with a diversified portfolio of orphan drugs.

2025 included the successful launch of KHINDIVI, the first FDA-approved oral solution formulation of hydrocortisone, in June. KHINDIVI was approved in May for pediatric patients five and older with adrenocortical insufficiency. The company is looking to expand the indication to younger patients with a revised formulation, and a bioequivalence study is expected to begin in early 2026.

The year also included high-performing relaunches of acquired assets Increlex, which treats a rare condition in which a child’s body does not produce enough growth factor-1, and the zinc therapy Galzin, a maintenance treatment for Wilson disease.

As of December, its portfolio included eight commercial products and five in its pipeline. The FDA is reviewing its new drug application for ET-600, with a decision scheduled for late February.

4. Fennec Pharmaceuticals (NASDAQ:FENC)

Year-to-date gain: 20.91 percent
Market cap: US$262.54 million
Share price: US$7.69

Fennec Pharmaceuticals is a commercial-stage specialty pharmaceutical company focused on preventing ototoxicity, meaning permanent hearing loss, in pediatric cancer patients undergoing cisplatin-based chemotherapy.

The company’s sole commercial product, Pedmark, is the first and only FDA-approved therapy specifically indicated to reduce the risk of hearing loss associated with cisplatin in patients one month of age and older with non-metastatic solid tumors.

Fennec experienced a pivotal year in 2025, marked by record revenue growth, entry into international markets and the elimination of corporate debt.

Additionally, data from a Phase 2/3 clinical study in Japan showed a significant reduction in the percentage of patients who experienced hearing loss, setting the stage for a 2026 global registration.

The company also began exploring its first major expansion into the adult cancer market through a new trial in metastatic testicular cancer.

5. Zevra Therapeutics (NASDAQ:ZVRA)

Year-to-date gain: 5.25 percent
Market cap: US$496.54 million
Share price: US$8.82

Zevra Therapeutics is a commercial-stage rare disease company that utilizes data-driven strategies to develop and commercialize transformational therapies for ultra-rare conditions.

Formerly known as KemPharm, the company rebranded in 2023 to reflect its evolution into a fully integrated pharmaceutical entity with a focus on high-unmet-need pediatric and metabolic disorders.

At the end of December, Zevra executed a strategic distribution agreement with Uniphar to provide its flagship product, Miplyffa, to patients outside of the US and Europe, broadening the drug’s global footprint. Miplyffa was approved by the FDA in 2024, and is indicated as a treatment for Niemann-Pick disease type C administered in combination with miglustat.

This announcement followed a strong Q3, in which the company reported a 605 percent year-over-year revenue increase, largely driven by the early success of Miplyffa.

Securities Disclosure: I, Meagen Seatter, hold no direct investment interest in any company mentioned in this article.

This post appeared first on investingnews.com

Sydney, Australia (ABN Newswire) – Locksley Resources Limited (ASX:LKY,OTC:LKYRF) (FRA:X5L) (OTCMKTS:LKYRF) advised that recent reconnaissance and surface sampling programs have successfully identified a consistent northwest to southeast oriented mineralised corridor at the Mojave Project.

HIGHLIGHTS

– Results from rock chip sampling returns 409g/t Ag confirming high-grade silver mineralisation ~3km from the initial high-grade silver discovery (Sample 258140), 320m southwest of the Desert Antimony Mine (DAM)

– Significant base metal mineralisation confirmed in addition to silver, with samples returning grades up to 4.2% Copper (Cu), 1.5% Lead (Pb), and 1.5% Zinc (Zn), highlighting the polymetallic nature of the system

– Twelve (12) rock chip samples exceeded 30g/t Ag, reinforcing additional precious and base metal potential within the Mojave Project’s North Block

– This discovery represents an important advancement in the Company’s exploration strategy and identifies a new, potentially high-value component of the Mojave Project

This discovery represents an important advancement in the Company’s exploration strategy and identifies a new, potentially high-value component of the Mojave Project. The delineation of a mineralised corridor suggests a strike extent approximately 2.4km westnorthwest of the Hendricks Shaft, and approximately 600m to the east-southeast, extending the mineralised corridor almost 3km from the Silver Prospect. This confirms the presence of a polymetallic quartz vein system, which includes the high-grade sample 258140 collected from a 3cm to 10cm wide vein (Figure 1*). These early results possibly suggest that the Ag-Pb-Zn-Cu mineralisation may reflect the presence of a large-scale hydrothermal system, which could potentially contain valuable concentrations of precious and base metals. Further exploration is required to test this concept.

Rock chip sampling within the Mojave Project’s North Block has returned results of up to 409g/t Ag, with associated base metal values of up to 1.5% Zn and 0.88% Pb, supporting the interpretation of a polymetallic mineralised system and enhancing the prospectivity of the corridor. Additional rock chip sample 258420 returned values up to 117g/t Ag, & 3.1% Cu, also located within the interpreted mineralised corridor located close to a historic adit and workings.

The interpreted mineralised corridor includes the historic Hendricks Shaft, located approximately 2.4km from the initial high-grade silver discovery. A total of 398 rock chip samples have been collected across the North Block with ~260 of these being collected along the mineralised corridor between DAM and up to 5.6km to the southeast.

Rock Chip Sampling Program Details

The recent sampling campaign was designed to test the strike extent of the high-grade silver mineralisation first identified in late 2024. The results (see Table 1) have exceededexpectations, confirming that the mineralised system extends significantly beyond the initial discovery zone (Sample 258140 – Figure 1*).

Key observations from the program include:

– Strike Extension: The mineralised corridor is now interpreted to extend from the Silver Prospect (Sample 258140) to historical trenches and stockpiles (Samples 258184 & 258185) located ~3km to the south-east significantly increasing the strike extent of the exploration target.

– Mineralisation Style: High-grade samples 258184 and 258185, collected from outcropping veins and historic stockpiles, exhibit quartz with gossanous selvages with boxwork textures. These are potential indicators of weathered sulphide-rich polymetallic veins, suggesting fresh sulphides may exist at depth.

– Visual Copper: Sample 258420 (which returned 117g/t Ag & 3.1% Cu) was collected from outcropping mineralisation at historic workings where copper carbonate (i.e. malachite) is visually prevalent (see Figure 3*). This confirms a copper component to the mineralised system.

Next Steps

Locksley will advance this exciting silver and base metal opportunity through a systematic exploration program run in parallel with ongoing activities at DAM and El Campo, comprising:

– Systematic Mapping: Detailed geological mapping between the Silver Prospect and the new south-eastern extension to define the structural geometry and continuity of the trend.

– Petrology and Geochemistry: Submission of samples for petrological interpretation to assist with determining relative timing of mineralisation and geochemical associations across the system.

– Geophysics: Assessment of geophysical survey options, such as Very Low Frequency electromagnetics (VLF-EM), Induced Polarisation (IP), or Electromagnetic (e.g. VTEM) to potentially identify mineralised zones and structures at depth that are not visible at surface.

– Drill Targeting: The goal of this work is to delineate high-priority drill-ready targets along the NW-SE corridor for future testing.

Additional work is planned to improve understanding of the corridor’s structural geometry, enabling more effective drill targeting and delineation of the extent and grade of mineralisation within the North Block.

Kerrie Matthews, Managing Director & CEO, commented:

‘Defining a 3km mineralised trend with surface results of up to 409 g/t silver and 1.5% copper is a highly encouraging outcome. Importantly, this discovery complements our core antimony development strategy and gives exposure as a diversified U.S. critical minerals company, providing shareholders with upside to precious metals, base metals, and strategic minerals within a single, high-quality project area.’

*To view tables and figures, please visit:
https://abnnewswire.net/lnk/R8C037M3

About Locksley Resources Limited:

Locksley Resources Limited (ASX:LKY,OTC:LKYRF) (FRA:X5L) (OTCMKTS:LKYRF) is an ASX listed explorer focused on critical minerals in the United States of America. The Company is actively advancing exploration across two key assets: the Mojave Project in California, targeting rare earth elements (REEs) and antimony. Locksley Resources aims to generate shareholder value through strategic exploration, discovery and development in this highly prospective mineral region.

Mojave Project

Located in the Mojave Desert, California, the Mojave Project comprises over 250 claims across two contiguous prospect areas, namely, the North Block/Northeast Block and the El Campo Prospect. The North Block directly abuts claims held by MP Materials, while El Campo lies along strike of the Mountain Pass Mine and is enveloped by MP Materials’ claims, highlighting the strong geological continuity and exploration potential of the project area.

In addition to rare earths, the Mojave Project hosts the historic ‘Desert Antimony Mine’, which last operated in 1937. Despite the United States currently having no domestic antimony production, demand for the metal remains high due to its essential role in defense systems, semiconductors, and metal alloys. With significant surface sample results, the Desert Mine prospect represents one of the highest-grade known antimony occurrences in the U.S.

Locksley’s North American position is further strengthened by rising geopolitical urgency to diversify supply chains away from China, the global leader in both REE & antimony production. With its maiden drilling program planned, the Mojave Project is uniquely positioned to align with U.S. strategic objectives around critical mineral independence and economic security.

Tottenham Project

Locksley’s Australian portfolio comprises the advanced Tottenham Copper-Gold Project in New South Wales, focused on VMS-style mineralisation

Source:
Locksley Resources Limited

Contact:
Kerrie Matthews
Chief Executive Officer
Locksley Resources Limited
T: +61 8 9481 0389
Kerrie@locksleyresources.com.au

News Provided by ABN Newswire via QuoteMedia

This post appeared first on investingnews.com

Here’s a quick recap of the crypto landscape for Monday (January 5) as of 9:00 p.m. UTC.

Get the latest insights on Bitcoin, Ether and altcoins, along with a round-up of key cryptocurrency market news.

Bitcoin and Ether price update

Bitcoin (BTC) was priced at US$94,127.01, up by 3.2 percent over 24 hours.

Bitcoin price performance, January 6, 2025.

Chart via TradingView.

Bitcoin started Monday strong, rising above US$92,000 in early trading before briefly breaking US$94,600, signaling a potential shift in near-term momentum after a bruising finish to 2025.

Research firm 10X said the move reflects a return to more normalized trading volumes and early signs of renewed institutional positioning at the start of the year. The firm notes that Bitcoin is holding above key moving averages, with the 21 day line emerging as a critical support level for maintaining upside bias.

It added that the shift suggests growing expectations for a push toward the US$100,000 level. The rebound follows three consecutive monthly declines — a historically rare pattern that has often preceded January recoveries.

“The strength across crypto and traditional safe havens reflects a rebalancing phase driven by geopolitical risk and liquidity positioning,” said Lacie Zhang, a research analyst at Bitget Wallet.

“In this setup, Bitcoin has room to push toward US$105,000, while Ethereum could test US$3,600, as traders balance inflation risks with crypto’s deflationary characteristics and long-term adoption narrative.’

Zhang said DeFi is currently driving significant growth, with protocols such as Uniswap (UNI) and Aave (AAVE) seeing benefits from improved governance, new revenue-sharing frameworks and institutional investor involvement.

“For large-cap altcoins, XRP and Solana stand out: XRP’s role in cross-border payments and improving regulatory clarity, combined with ETF inflows, could support price ranges of US$5 – US$10, while Solana’s high-throughput ecosystem and network expansion position it for US$500 – US$800 over the next growth phase.

“The renewed surge in memecoin activity reflects improving retail risk appetite,” she added. “It’s not a long-term thesis, but often a precursor to liquidity rotating into higher-quality, utility-driven altcoins as the cycle matures.”

Ether (ETH) was priced at US$3,239.82, up by 3.2 percent over the last 24 hours.

Altcoin price update

  • XRP (XRP) was priced at US$2.31, up by 10.4 percent over 24 hours.
  • Solana (SOL) was trading at US$137.92, up by three percent over 24 hours.

Today’s crypto news to know

Crypto investment products pull in US$47.2 billion in 2025

Global crypto exchange-traded products attracted US$47.2 billion in net inflows in 2025, falling just short of the prior year’s record despite a noticeable slowdown in Bitcoin demand, according to CoinShares.

Bitcoin-focused products added US$26.9 billion, a sharp drop from 2024 levels, as price weakness dampened inflows and modest interest emerged in short-bitcoin vehicles. The cooling in Bitcoin was offset by a surge into select altcoins, led by Ethereum products, which posted US$12.7 billion in inflows.

Meanwhile, XRP and Solana funds followed closely as each recorded multibillion-dollar inflows and triple-digit percentage growth year over year.

Japan signals crypto integration across traditional markets

Satsuki Katayama, Japan’s finance minister, has signaled stronger government backing for integrating digital assets into the country’s stock and commodities exchanges.

Speaking at the Tokyo Stock Exchange, she emphasized the role of exchanges in expanding public access to blockchain-based assets and modern investment tools. She pointed to the US experience with crypto-linked exchange-traded funds (ETFs) as a reference point, even as Japan currently lacks domestically listed crypto ETFs.

Katayama described 2026 as a “digital year,” pledging policy support for exchanges adopting advanced trading technologies. The remarks build on regulatory reforms already underway, including discussions on allowing banks to hold crypto assets and the approval of Japan’s first yen-pegged stablecoin.

Bitget’s tokenized stock milestone and TradFi launch

Bitget’s new Universal Exchange vision has reached two major milestones that signal a major shift in how digital and traditional assets are traded in one place. Bitget announced last week that its tokenized stock volume surpassed US$1 billion, with 95 percent of that total volume occurring in December alone.

Building on that momentum, and following a successful private beta with over 80,000 users, today Bitget officially opened its TradFi trading suite to the public, allowing customers access to 79 different instruments across forex, metals, indices and commodities. These products are traded as contracts for difference and are settled entirely in USDT, meaning crypto-native traders can execute macro strategies without leaving the platform or converting to fiat currency.

During the test phase, XAU/USD recorded over US$100 million in single-day trading volume, one of the highest daily figures observed during the beta.

“Traders want the flexibility to choose between assets in a unified ecosystem,” said Chen.

“They want the freedom to move between crypto and traditional markets as conditions change. TradFi going public is about giving them that accessibility in one place, without friction.”

The move signals a broader shift in how exchanges are evolving, not just as venues for speculation, but as comprehensive gateways to global markets under a unified trading experience.

Securities Disclosure: I, Meagen Seatter, hold no direct investment interest in any company mentioned in this article.

Securities Disclosure: I, Giann Liguid, hold no direct investment interest in any company mentioned in this article.

This post appeared first on investingnews.com

Perth, Australia (ABN Newswire) – Altech Batteries Ltd (ASX:ATC,OTC:ALTHF) (FRA:A3Y) (OTCMKTS:ALTHF) announced that binding conditional funding approval in the amount of 46.11 million Euro has now been granted for the CERENERGY(R) Sodium-Chloride Solid-State battery project in Saxony, Germany. The grant approval materially derisks project funding and supports progression toward construction of the planned 120 MWh CERENERGY(R) battery manufacturing facility in Saxony, Germany.

Highlights

– Altech Batteries GmbH’s CERENERGY(R) battery project has received conditional binding funding approval under Germany’s federal ‘STARK’ economic development program.

– The approval relates to a grant covering approximately 30% of eligible project CAPEX, with funding of up to EUR46.11M.

– The funding commitment is conditional on achieving full project financial close by 30 June 2026 and parliamentary approval of funds under Germany’s 2026 Federal Budget.

Conditional Binding Funding Commitment

The funding is being provided as part of the federal STARK program, which is supported by the Federal Ministry for Economic Affairs and Energy in cooperation with the EU. The aim of this program is to lead regions undergoing structural change into an ecologically, economically and socially sustainable future.

With the approval of the funding, the project has successfully completed the second and decisive stage of the approval process. The funding covers approximately 30% of the eligible investment costs and represents a significant milestone for the construction of the planned 120 MWh CERENERGY(R) battery factory in Germany.

This decision underscores the importance of the innovative CERENERGY(R) technology, which is being developed in collaboration with the Fraunhofer Society. The Sodium-Chloride Solid-State battery offers a safe, sustainable and strategically independent alternative to lithium-ion batteries and is expected to play an important role in future stationary energy storage solutions – especially for the European market.

Mr Daniel Raihani, Managing Director & Chief Executive Officer, commented ‘Securing conditional binding funding approval of up to EUR46.11 million under Germany’s STARK program is a major milestone for the CERENERGY(R) project. The support reflects the strategic importance of establishing advanced, nonlithium energy storage manufacturing capability in Europe and recognises the technical progress achieved to date in collaboration with Fraunhofer IKTS.

‘Importantly, the grant materially de-risks the project’s capital structure by covering approximately 30% of eligible investment costs and provides a strong foundation as we progress toward full project financing and construction of the planned 120 MWh production facility in Saxony, Germany.

‘We remain focused on completing financial close by mid-2026 and advancing the CERENERGY(R) technology toward commercial deployment to support long-duration, safe and sustainable stationary energy storage solutions for the European market’.

As is customary for projects of this size, the funding commitment is subject to final financial close of the CERENERGY(R) battery project by June 2026 and budgetary approval of the funds in the 2026 federal budget.

*To view tables and figures, please visit:
https://abnnewswire.net/lnk/918BT5H8

About Altech Batteries Ltd:

Altech Batteries Limited (ASX:ATC,OTC:ALTHF) (FRA:A3Y) is a specialty battery technology company that has a joint venture agreement with world leading German battery institute Fraunhofer IKTS (‘Fraunhofer’) to commercialise the revolutionary CERENERGY(R) Sodium Alumina Solid State (SAS) Battery. CERENERGY(R) batteries are the game-changing alternative to lithium-ion batteries. CERENERGY(R) batteries are fire and explosion-proof; have a life span of more than 15 years and operate in extreme cold and desert climates. The battery technology uses table salt and is lithium-free; cobalt-free; graphite-free; and copper-free, eliminating exposure to critical metal price rises and supply chain concerns.

The joint venture is commercialising its CERENERGY(R) battery, with plans to construct a 100MWh production facility on Altech’s land in Saxony, Germany. The facility intends to produce CERENERGY(R) battery modules to provide grid storage solutions to the market.

Source:
Altech Batteries Ltd

Contact:
Daniel Raihani
Managing Director
Altech Batteries Limited
Tel: +61-8-6168-1555
Email: info@altechgroup.com

Martin Stein
Chief Financial Officer
Altech Batteries Limited
Tel: +61-8-6168-1555
Email: info@altechgroup.com

News Provided by ABN Newswire via QuoteMedia

This post appeared first on investingnews.com

Investor Insight

Centurion Minerals offers investors an early-stage entry point into a strategically located gold exploration company positioned within one of North America’s most prolific and active mining districts. With a restructured corporate foundation, and a highly experienced geological and corporate finance team, the company is primed for value-creating discoveries.

investingnews.com

Overview

Centurion Minerals (TSXV:CTN) is a Canadian exploration company focused on the acquisition, exploration and development of precious metals projects in the Americas.

The company’s strategy is centered on advancing high-quality, early-stage gold assets through systematic exploration to define drill-ready targets and unlock the discovery potential inherent in its three-part claim package: the Newman, Noseworthy and Hepburn properties. Situated near major operations and new discoveries, these claims benefit from excellent infrastructure, year-round road access and proximity to proven mineralized structural corridors. Centurion intends to increase shareholder value through targeted geophysics, ground truthing and drilling programs designed to reveal new high-grade zones, as well as through potential future acquisitions of complementary gold assets across the Americas.

Backed by a leadership team with decades of exploration, geology, corporate finance and project development experience, Centurion is positioned to capitalize on strong gold market fundamentals and renewed investor interest in junior exploration companies. With a low current valuation and advancing work program, the company provides leverage to both exploration success and broader trends in the gold sector.

Company Highlights

  • Highly prospective gold project in a world-class district located in the central north Abitibi greenstone belt, adjacent to major deposits and producing mines including Hecla Mining’s (NYSE:HL) Casa Berardi mine and Agnico Eagle’s (TSX:AEM) Detour Lake operations.
  • Exceptional closeology advantage, with its Casa Berardi West project situated just 12 km from AMEX Exploration’s (TSXV:AMX) 1.6 Moz “Perron” discovery and along the same structural corridors that have produced multi-million-ounce deposits.
  • Significant historic drilling across the three claim groups, including results up to 38 g/t gold and multiple intervals indicating gold-bearing iron formations and shear zones.
  • Clear exploration strategy including historic data compilation, geophysical surveys, target generation and a planned program to define new mineralized zones.
  • Experienced management and technical team with decades of experience in mineral exploration, and international corporate finance, enhances the potential of uncovering additional exploration opportunities.
  • Low market capitalization and recently reactivated corporate structure, offering investors a low entry point ahead of meaningful upside catalysts.

Key Project

Casa Berardi West Gold Project

The Casa Berardi West project is Centurion’s flagship gold exploration asset, encompassing approximately 6,732 hectares across three contiguous claim groups – Newman, Noseworthy and Hepburn – located 66 km northeast of Cochrane, Ontario. The project sits along structural corridors that host some of the region’s most significant deposits, including Hecla Mining’s Casa Berardi mine (3 Moz past production, plus 4 Moz in reserves and resources), Agnico Eagle’s Detour Lake mine (15 Moz reserve, producing ~659,000 oz of gold per year ), and AMEX Exploration’s Perron discovery (1.6 Moz measured and indicated resource at 6.14 g/t gold).

Location of the three claim groups at Casa Berardi West

Geological Setting & Closeology Advantage

The project is situated within the central north Abitibi Subprovince, an Archean greenstone belt known globally for its prolific endowment of gold and base metals. The claims lie adjacent to geological features associated with multiple major deposits – iron formations, shear zones and VMS trends – creating strong analogues to high-grade gold mines such as the Musselwhite mine in Northern Ontario.

This “closeology” positioning significantly enhances the potential for Centurion’s ground to host similar mineralization.

Historic Results & Target Areas

Historic exploration across the Casa Berardi West project – spanning more than 70 RC and diamond drill holes – has already confirmed the presence of gold-bearing structures and favorable host rocks. Notably, previous work returned multiple samples above 1 g/t gold, including a standout result of 38 g/t gold, demonstrating strong mineralization potential across the claim area.

Significant historic drill results at Newman target

Across the three claim groups, drilling and geophysical surveys have identified key geological features associated with major deposits in the region, including iron formations, shear zones and sulphidized horizons. Several zones of interest remain untested or underexplored, particularly along structural trends that extend from nearby high-grade gold and VMS systems such as the Perron and Normetal areas.

These findings provide Centurion with multiple high-priority target areas for follow-up exploration, forming the foundation for its next phase of geophysical work and upcoming drill targeting.

Management Team

David Tafel – Director, President and CEO

David Tafel brings over 30 years of experience in corporate structuring, strategic planning, financing and executive management across multiple public and private resource companies. He has raised several hundred million dollars for ventures in mining, technology and life sciences, and previously managed private investment funds at Canada’s largest independent securities firm.

Jeremy Wright – Director and CFO

A seasoned financial executive with more than 20 years of experience, Jeremy Wright serves as president & CEO of Seatrend Strategy Group and has held CFO roles across numerous public companies in the resource and technology sectors. His background includes financial management, negotiations and environmental economics, supported by extensive board leadership experience.

Joseph Del Campo – Director

Joseph Del Campo has served as CFO and Interim CEO across several mining companies, including Unigold and First Nickel. With decades of corporate financial leadership and board experience, he contributes deep governance, audit and operational oversight expertise to Centurion’s board.

Mike Kilbourne – Geological Consultant

A veteran geologist with 40+ years of industry experience, Mike Kilbourne has managed over 100,000 metres of drilling across North America and Mexico, worked as a production geologist in multiple mining environments, and generated over 700 exploration targets for private and public companies.

Jamie Lavigne – Geological Consultant

Jamie Lavigne is a senior exploration geologist with more than 30 years of experience in base and precious metals. He has held senior technical roles with major mining companies and specializes in advanced exploration, resource delineation and geological modeling across global mineral belts.

This post appeared first on investingnews.com

From established players to up-and-coming firms, Canada’s pharmaceutical landscape is diverse and dynamic.

Canadian drug companies are working to discover and develop major innovations amidst an increasingly competitive global landscape. Rising technologies such as artificial intelligence are playing a role in the landscape as well.

Read on to learn about what’s been driving the share prices of the best-performing Canadian pharma stocks.

1. HLS Therapeutics (TSX:HLS)

Year-on-year gain: 26.6 percent
Market cap: C$149.8 million
Share price: C$4.76

HLS Therapeutics focuses on drugs for cardiovascular and central nervous system problems, often through partnerships. The company specializes in acquiring and commercializing pharmaceuticals that address unmet needs, including Vascepa to reduce cardiovascular risk and Clozaril for treatment-resistant schizophrenia.

HLS in-licensed the exclusive rights to the treatments Nilemdo and Nexlizet, both of which are already approved in other countries, from Esperion (NASDAQ:ESPR) in May.

The November 2025 Health Canada approval of LDL-cholesterol lowering treatment Nilemdo represents the most significant catalyst for the company since the launch of Vascepa, positioning HLS as a dominant leader in the Canadian cardiovascular market. The company is targeting Nilemdo’s commercial launch in Q2 2026.

Along with the approval, Health Canada issued a notice of non-compliance for its Nexlizet cholesterol-reducing treatment. According to HLS, the decision was related to chemistry, manufacture and controls data, not clinical data or safety.

Additionally, the company generates revenue from a diversified portfolio of royalty interests on various products marketed by third parties.

2. Satellos Bioscience (TSXV:MSCL)

Year-on-year gain: 14.49 percent
Market cap: C$141.04 million
Share price: C$0.79

Satellos Bioscience is a Canadian pharmaceutical company expanding treatment options for muscle disorders. The company has focused specifically on Duchenne muscular dystrophy, developing therapies that target the specific biological pathways involved in regenerating and repairing muscle tissue.

Its lead candidate, SAT-3247, targets a protein called AAK1, which regulates the activity of stem cells that activate and differentiate new muscle fibers.

In Q4 2025, Satellos administered the first dose to a patient in its 11-month open-label follow-up study for adults who completed its initial Phase 1b trial. The study seeks to demonstrate the lasting impact of the significant functional improvements observed earlier in the year.

On December 9, the company received Investigational New Drug (IND) clearance from the US Food and Drug Administration (FDA) and several other global regulators to initiate BASECAMP, a global Phase 2 randomized, placebo-controlled study to evaluate SAT-3247 in pediatric patients.

3. Knight Therapeutics (TSX:GUD)

Year-on-year gain: 14.29 percent
Market cap: C$592.59 million
Share price: C$6.00

Knight Therapeutics is a specialty pharmaceutical company headquartered in Montreal, Québec. It operates on an acquisition and in-licensing model, obtaining the rights to innovative medicines from global pharmaceutical companies and commercializing them across Canada and Latin America.

The company was originally founded by the former leaders of Paladin Labs, which was acquired by Endo International in 2014. In June 2025, Knight bought the Paladin business back from Endo for C$107 million, adding over 40 products to Knight’s Canadian roster.

The additions, helped drive 32 percent revenue growth year-over-year to a record C$122.55 million in Q3. The company projects its Knight Canada subsidiary will be the company’s top revenue-contributor within two years.

4. BioSyent (TSXV:RX)

Year-on-year gain: 10.07 percent
Market cap: C$146.89 million
Share price: C$12.90

BioSyent is a specialty pharmaceutical company focused on in-licensing or acquiring established, high-margin healthcare products for the Canadian and international markets. Its growth is anchored by brands in iron health and women’s wellness. Its flagship brand, FeraMAX, has been Canada’s leading iron supplement for over a decade.

The company’s 2024 acquisition of Tibella, a treatment for menopausal symptoms, has been a major growth driver. According to its Q3 earnings report. BioSyent’s sales grew 19 percent year-over-year in Canada and 94 percent in the international market.

5. NurExone Biologic (TSXV:NRX)

Year-on-year gain: 6.45 percent
Market cap: C$47.54 million
Share price: C$0.66

NurExone Biologic is behind ExoTherapy, a drug-delivery platform that uses exosomes, which are nano-sized extracellular vesicles, to create treatments for central nervous system disorders, spinal cord injuries and traumatic brain injuries. It is a less invasive alternative to cell transplantation, which requires surgery and carries the risk of rejection.

NurExone’s first nano-drug, ExoPTEN, uses a proprietary sIRNA sequence delivered with the ExoTherapy platform to treat spinal cord injuries. ExoPTEN received orphan drug designation from the US FDA in October 2023.

The company expects to initiate its Phase 1/2a first-in-human trial for acute spinal cord injury in the second half of 2026, targeting patients with traumatic injuries.

It continues to make significant progress, with recent preclinical studies demonstrating strong, dose-dependent vision recovery in glaucoma models and improved motor function in spinal cord injury models.

The company announced plans for a US exosome production facility in Indianapolis, Indiana, in September. According to the release, ‘The GMP compliant site would produce exosomes both for NurExone’s therapeutic pipeline and for a growing business-to-business opportunity in regenerative aesthetics.’

In December, the company began planning for small-scale production of ExoPTEN in Israel to support its clinical trial.

Securities Disclosure: I, Meagen Seatter, hold no direct investment interest in any company mentioned in this article.

This post appeared first on investingnews.com